Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Higher baseline NLR is associated with increased cardiovascular risk in ACS/PCI patients. Relative risk reductions with evolocumab were consistent across NLR categories, while absolute risk reductions were more significant in high-NLR patients. Minimized risk is observed in patients with the lowest on-treatment NLR and LDL-C levels.
Authors
- Yanghui Zhang (ORCID: https://orcid.org/0000-0003-2189-3496)
- Xiangwei Bo (ORCID: https://orcid.org/0000-0001-9436-112X)
- Tingting Xiao (ORCID: https://orcid.org/0000-0001-7311-4496)
- Huan Liu (ORCID: https://orcid.org/0000-0002-0253-647X)
- Kui Chen (ORCID: https://orcid.org/0000-0002-3910-1402)
- Yanyun Zhang (ORCID: https://orcid.org/0000-0002-8990-8220)
- K. Li (ORCID: https://orcid.org/0000-0001-8442-5695)
- Jiandong Ding
- Orion I. R. Chiara Villamil
Institutions
- Zhongda Hospital Southeast University (CN)
- Yancheng Third People's Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Southeast University (CN)
Publication Details
- Journal
- Lipids in Health and Disease
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1186/s12944-025-02537-2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00